137 related articles for article (PubMed ID: 38575077)
1. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood-tumor barrier for boosted brain tumor therapy.
Mu R; Sun H; Zeng Y; Tong Y; Tang P; Zhao M; Lv Z; Yu J; Chen Y; Lan Q; Zhen X; Han L
J Control Release; 2024 May; 369():458-474. PubMed ID: 38575077
[TBL] [Abstract][Full Text] [Related]
2. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.
Zhou W; Chen C; Shi Y; Wu Q; Gimple RC; Fang X; Huang Z; Zhai K; Ke SQ; Ping YF; Feng H; Rich JN; Yu JS; Bao S; Bian XW
Cell Stem Cell; 2017 Nov; 21(5):591-603.e4. PubMed ID: 29100012
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
4. Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.
Guerra DAP; Paiva AE; Sena IFG; Azevedo PO; Silva WN; Mintz A; Birbrair A
Angiogenesis; 2018 Nov; 21(4):667-675. PubMed ID: 29761249
[TBL] [Abstract][Full Text] [Related]
5. Prodrug Delivery Using Dual-Targeting Nanoparticles To Treat Breast Cancer Brain Metastases.
Ju X; Chen H; Miao T; Ni J; Han L
Mol Pharm; 2021 Jul; 18(7):2694-2702. PubMed ID: 34109794
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
Lyle LT; Lockman PR; Adkins CE; Mohammad AS; Sechrest E; Hua E; Palmieri D; Liewehr DJ; Steinberg SM; Kloc W; Izycka-Swieszewska E; Duchnowska R; Nayyar N; Brastianos PK; Steeg PS; Gril B
Clin Cancer Res; 2016 Nov; 22(21):5287-5299. PubMed ID: 27245829
[TBL] [Abstract][Full Text] [Related]
7. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases.
Guo Q; Zhu Q; Miao T; Tao J; Ju X; Sun Z; Li H; Xu G; Chen H; Han L
J Control Release; 2019 Jun; 303():117-129. PubMed ID: 31026546
[TBL] [Abstract][Full Text] [Related]
8. Salvianolic acid A increases the accumulation of doxorubicin in brain tumors through Caveolae endocytosis.
Zhang C; Pan Y; Cai R; Guo S; Zhang X; Xue Y; Wang J; Huang J; Wang J; Gu Y; Zhang Z
Neuropharmacology; 2020 May; 167():107980. PubMed ID: 32014448
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
11. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
Wen L; Tan Y; Dai S; Zhu Y; Meng T; Yang X; Liu Y; Liu X; Yuan H; Hu F
Drug Deliv; 2017 Nov; 24(1):1843-1855. PubMed ID: 29182025
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
[TBL] [Abstract][Full Text] [Related]
13. Targeting microbubbles-carrying TGFβ1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors.
Chen YC; Chiang CF; Wu SK; Chen LF; Hsieh WY; Lin WL
J Control Release; 2015 Aug; 211():53-62. PubMed ID: 26047759
[TBL] [Abstract][Full Text] [Related]
14. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
15. PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases.
Ni J; Miao T; Su M; Khan NU; Ju X; Chen H; Liu F; Han L
J Control Release; 2021 Jan; 329():934-947. PubMed ID: 33069744
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
18. Suppressing Wnt signaling of the blood‒tumor barrier to intensify drug delivery and inhibit lipogenesis of brain metastases.
Tong Y; An P; Tang P; Mu R; Zeng Y; Sun H; Zhao M; Lv Z; Wang P; Han W; Gui C; Zhen X; Han L
Acta Pharm Sin B; 2024 Jun; 14(6):2716-2731. PubMed ID: 38828148
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites.
Ashokan A; Sarkar S; Kamran MZ; Surnar B; Kalathil AA; Spencer A; Dhar S
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2318119121. PubMed ID: 38709930
[TBL] [Abstract][Full Text] [Related]
20. Lnc00462717 regulates the permeability of the blood-brain tumor barrier through interaction with PTBP1 to inhibit the miR-186-5p/Occludin signaling pathway.
Zhang C; Zhang X; Wang J; Di F; Xue Y; Lin X; Zhang Y; Zhang H; Zhang Z; Gu Y
FASEB J; 2020 Aug; 34(8):9941-9958. PubMed ID: 32623796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
